Parenteral nutrition market dominated by Baxter

The parenteral nutrition market has been forecast to increase at a compound annual growth rate (CAGR) of 6.3% over the next six years, increasing from a valuation of $2.9 billion in 2011, to hit a market value of $4,861 million by 2018.

Parenteral nutrition is intravenous (IV) administration of nutrition, which may include protein, carbohydrates, lipids (fats), vitamins and other trace elements for patients who cannot ingest food orally or enterally (tube-fed).

Many patients depend on parenteral nutrition as a life-sustaining therapy. However, in the past year, troubling circumstances have impacted the safe prescription, formulation and delivery of nutrition support.

The parenteral nutrition market is rapidly growing due to the increasing incidence of diseases such as cancer, AIDS and GI disorders including short bowel syndrome, ischemic bowel disease, pseudo obstruction and Crohn's disease. The other major factor driving growth of the parenteral nutrition market is an increase in the elderly population in the developed countries.

In 2009, approximately 390,000 patients in the major markets of the US, EU and Canada used parenteral nutrition products, accounting for total product sales of $1.3 billion. Through 2014, the total number of parenteral nutrition users will rise by 10% per year to 628,000.

The US market, with sales worth $1,476 million in 2011, accounted for 50.7% of the total parenteral nutrition market. The market in the top five countries in Europe was estimated to be $1,275 million, the second largest parenteral nutrition market, and to have grown at a CAGR of 5.4% between 2004 and 2011. The parenteral nutrition market in Japan registered a share of 5.4% of the total parenteral nutrition market, accounting for $157 million sales value in 2011.

The PN market M&A landscape demonstrated a fairly moderate level of activity between 2004 and 2010, with seven major acquisition deals signed during the time period.

Four manufacturers currently jockey for share in this closely held market: market leader Baxter, enteral and parenteral products suppliers Fresenius Kabi and B. Braun, and Hospira. Although the introduction of new parenteral solutions is infrequent, these four players are differentiating themselves through hardware improvements, expanded pediatric labeling, new product formats and enhanced systems and services for home use.

For more information on the parenteral nutrition market, see the latest research: Parenteral Nutrition Market

Follow us on Twitter @CandMResearch